Biogen Idec Inc (BIIB): Biogen Idec 5-Year Revenue Outlook Seeking Alpha In its drug pipeline, the company is conducting phase 3 trials on Daclizumab (ant-CD25) for multiple sclerosis. The phase 3 data are expected mid-2014. Biogen is also conducting several phase 2 clinical trials, in which the interim results will be ... |
